Clinical Trial Update: L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating L-Arginine and Spironolactone for dialysis-dependent end-stage renal disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• L-Arginine (L-Arginine)
• Spironolactone (spironolactone)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: End Stage Renal Disease, Hemodialysis | Phase 4 | Status: WITHDRAWN